Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20304613 | 0.93 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL20304787 | 0.90 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL20304822 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL20304775 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL20304769 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL20304767 | 0.85 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL21578817 | 0.85 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL20304708 | 0.85 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL20304682 | 0.84 | CNR1 (0.81) | CNR1CNR2 | |
| SCHEMBL21578816 | 0.84 | CNR1 (0.77) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696677-B2 | Diaryl purine derivatives with improved bioavailability | RESEARCH TRIANGLE INSTITUTE (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190352305-A1 | DIARYL PURINE DERIVATIVES WITH IMPROVED BIOAVAILABILITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-11-21 | — | — | US | disclosed |
| EP-3558996-A1 | DIARYL PURINE DERIVATIVES WITH IMPROVED BIOAVAILABILITY | Research Triangle Institute, International (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119076-A1 | DIARYL PURINE DERIVATIVES WITH IMPROVED BIOAVAILABILITY | RESEARCH TRIANGLE INSTITUTE (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696677-B2 | Diaryl purine derivatives with improved bioavailability | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885 |
| US-20190352305-A1 | DIARYL PURINE DERIVATIVES WITH IMPROVED BIOAVAILABILITY | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.